Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs

A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis

(2018) Marjorie Z. Imperial et al.   NATURE MEDICINE

Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility

(2018) Bai-Yu Lee et al.   PLoS One

World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update

(2017) Dennis Falzon et al.   EUROPEAN RESPIRATORY JOURNAL

Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease

(2017) H-Y. Yoon et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time

(2017) Bai-Yu Lee et al.   Nature Communications

NOS2-deficient mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans

(2017) Martin Gengenbacher et al.   Scientific Reports

Anti-Mycobacterium tuberculosis activity of antituberculosis drugs and amoxicillin/clavulanate combination

(2016) Aline Daniele Furlan Pagliotto et al.   JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model

(2016) Aleidy Silva et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform

(2016) Ali Zarrinpar et al.   Science Translational Medicine

In VitroActivity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates

(2015) Dan Zhang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

QTc prolongation and treatment of multidrug-resistant tuberculosis

(2015) E. Harausz et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis

(2015) Sandeep Tyagi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Delamanid expanded access novel treatment of drug resistant tuberculosis

(2015) Roxana Rustomjee et al.   Infection and Drug Resistance

Assessment of Clofazimine Activity in a Second-Line Regimen for Tuberculosis in Mice

(2013) Jacques H. Grosset et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

In VitroandIn VivoEfficacy of β-Lactams against Replicating and Slowly Growing/Nonreplicating Mycobacterium tuberculosis

(2013) Suresh Solapure et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Modern Lineages of Mycobacterium tuberculosis Exhibit Lineage-Specific Patterns of Growth and Cytokine Induction in Human Monocyte-Derived Macrophages

(2012) Rajesh Sarkar et al.   PLoS One

The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis

(2012) Borna Müller et al.   TRENDS IN GENETICS

Short-Course Chemotherapy with TMC207 and Rifapentine in a Murine Model of Latent Tuberculosis Infection

(2011) Tianyu Zhang et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Sterilizing Activity of Novel TMC207- and PA-824-Containing Regimens in a Murine Model of Tuberculosis

(2011) Rokeya Tasneen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Pharmacodynamics of TMC207 and ItsN-Desmethyl Metabolite in a Murine Model of Tuberculosis

(2011) Marie-Claude Rouan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Systematic quantitative characterization of cellular responses induced by multiple signals

(2011) Ibrahim Al-Shyoukh et al.   BMC Systems Biology

Nitroimidazoles for the treatment of TB: past, present and future

(2011) Tathagata Mukherjee et al.   Future Medicinal Chemistry

Global tuberculosis drug development pipeline: the need and the reality

(2010) Zhenkun Ma et al.   LANCET

The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin

(2010) Radhika Gupta et al.   NATURE MEDICINE

Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis

(2009) Evan W Orenstein et al.   LANCET INFECTIOUS DISEASES

Isoniazid or Moxifloxacin in Rifapentine-based Regimens for Experimental Tuberculosis?

(2008) Ian M. Rosenthal et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis

(2008) E. Nuermberger et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis

(2008) R. Rustomjee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The metabolic activity of Mycobacterium tuberculosis, assessed by use of a novel inducible GFP expression system, correlates with its capacity to inhibit phagosomal maturation and acidification in human macrophages

(2008) Bai-Yu Lee et al.   MOLECULAR MICROBIOLOGY